D-0759-2023 Class II Terminated
FDA drug recall D-0759-2023 was initiated by Amerisource Health Services LLC on March 17, 2023 and is designated Class II. Reason for recall: CGMP Deviations: recalling drug products following an FDA inspection. The recall status is terminated (terminated September 6, 2024). Affected quantity: 129,849 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- May 31, 2023
- Initiation Date
- March 17, 2023
- Termination Date
- September 6, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 129,849 bottles
Product Description
Glimepiride Tablets, USP, 4 mg, RX, Packaged as a) 100-count bottle, NDC# 68001-179-00; b) 500-count bottle, NDC# 68001-179-03, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. INDIA. For BluePoint Laboratories
Reason for Recall
CGMP Deviations: recalling drug products following an FDA inspection.
Distribution Pattern
Nationwide USA
Code Information
Batches a) P2003403, EXP 05/31/2023; P2006593, EXP 11/30/2023; P2101152, EXP 01/31/2024; P2105014, EXP 06/30/2024; R2101440, EXP 09/30/2024; P2200774, EXP 01/31/2025; R2200664, EXP 04/30/2025 b) P2100705, EXP 01/31/2024; P2104672, EXP 06/30/2024; R2101435, EXP 09/30/2024; R2200102, EXP 12/31/2024; R2200577, EXP 04/30/2025; P2205870, EXP 08/31/2025 [500 count] Lot, expiry: P2100121, exp 11/30/2023; P2100705, exp 01/31/2024; P2104672, exp 06/30/2024; R2101435, exp 09/30/2024; R2200102, exp 12/31/2024; R2200577, exp R2200577;P2205870, exp 08/31/2025